Table 2.
Comparative univariate survival analysis of UTUC patients receiving NU.
| Univariate analysis | OS | CSS | DFS | BRFS | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | ||||||||||
| Group | 0.396 | 0.340 | 0.432 | 0.772 | |||||||||||||
| LND (-) | 1 | 1 | 1 | 1 | |||||||||||||
| LND (+) | 1.165 (0.818, 1.659) | 1.222 (0.810, 1.844) | 1.131 (0.833, 1.535) | 1.049 (0.758, 1.451) | |||||||||||||
| Sex | 0.901 | 0.694 | 0.395 | <0.001** | |||||||||||||
| Male | 1 | 1 | 1 | 1 | |||||||||||||
| Female | 0.980 (0.710, 1.352) | 0.927 (0.634, 1.354) | 0.885 (0.669, 1.172) | 0.573 (0.426, 0.770) | |||||||||||||
| Age | 0.003** | 0.172 | 0.419 | 0.770 | |||||||||||||
| <70 | 1 | 1 | 1 | 1 | |||||||||||||
| >=70 | 1.633 (1.178, 2.263) | 1.304 (0.891, 1.907) | 1.123 (0.848, 1.488) | 1.045 (0.779, 1.400) | |||||||||||||
| Histological variant | 0.043* | 0.120 | 0.070 | 0.729 | |||||||||||||
| No | 1 | 1 | 1 | 1 | |||||||||||||
| Yes | 1.540 (1.014, 2.337) | 1.482 (0.902, 2.434) | 1.420 (0.972, 2.075) | 0.924 (0.592, 1.444) | |||||||||||||
| ECOG scores | <0.001** | <0.001** | 0.014* | 0.836 | |||||||||||||
| 0~1 | 1 | 1 | 1 | 1 | |||||||||||||
| 2~4 | 2.905 (1.991, 4.238) | 2.465 (1.549, 3.923) | 1.634 (1.105, 2.415) | 0.951 (0.591, 1.531) | |||||||||||||
| Tumor size | |||||||||||||||||
| <1cm | 1 | 1 | 1 | 1 | |||||||||||||
| ≥1 & < 2 cm | 2.742 (0.649, 11.576) | 0.170 | 3.485 (0.463, 26.248) | 0.225 | 1.082 (0.373, 3.142) | 0.885 | 0.850 (0.377, 1.918) | 0.696 | |||||||||
| ≥2 & < 3 cm | 2.199 (0.525, 9.209) | 0.281 | 3.180 (0.428, 23.618) | 0.258 | 1.481 (0.531, 4.131) | 0.453 | 0.776 (0.349, 1.728) | 0.535 | |||||||||
| ≥ 3cm | 2.935 (0.722, 11.932) | 0.132 | 4.166 (0.577, 30.055) | 0.157 | 1.987 (0.734, 5.380) | 0.177 | 0.769 (0.357, 1.657) | 0.502 | |||||||||
| Tumor location | |||||||||||||||||
| Renal pelvis | 1 | 1 | 1 | 1 | |||||||||||||
| Ureter | 1.361 (0.947, 1.957) | 0.096 | 1.307 (0.849, 2.012) | 0.223 | 1.217 (0.885, 1.647) | 0.227 | 1.275 (0.911, 1.785) | 0.156 | |||||||||
| Synchronous | 1.442 (0.940, 2.213) | 0.094 | 1.489 (0.905, 2.449) | 0.117 | 1.397 (0.964, 2.023) | 0.077 | 1.829 (1.255, 2.664) | 0.002** | |||||||||
| Multiplicity | 0.026* | 0.004** | 0.006** | 0.001** | |||||||||||||
| No | 1 | 1 | 1 | 1 | |||||||||||||
| Yes | 1.447 (1.045, 2.003) | 1.761 (1.202, 2.578) | 1.494 (1.124, 1.987) | 1.671 (1.241, 2.249) | |||||||||||||
| History of BC | |||||||||||||||||
| No | 1 | 1 | 1 | 1 | |||||||||||||
| Previous BC | 2.332 (1.253, 4.338) | 0.008** | 2.422 (1.167, 5.024) | 0.018* | 1.640 (0.888, 3.028) | 0.114 | 3.214 (1.881, 5.493) | <0.001** | |||||||||
| Concurrent BC | 1.749 (1.140, 2.682) | 0.010* | 2.117 (1.317, 3.405) | 0.002** | 1.999 (1.398, 2.860) | <0.001** | 1.926 (1.314, 2.823) | 0.001** | |||||||||
| Preoperative hydronephrosis | <0.001** | 0.005** | 0.088 | 0.383 | |||||||||||||
| No | 1 | 1 | 1 | 1 | |||||||||||||
| Yes | 2.109 (1.405, 3.167) | 1.966 (1.229, 3.147) | 1.311 (0.960, 1.790) | 1.151 (0.839, 1.577) | |||||||||||||
| Lymphovascular invasion | 0.019* | 0.002** | <0.001** | 0.112 | |||||||||||||
| No | 1 | 1 | 1 | 1 | |||||||||||||
| Yes | 1.502 (1.071, 2.107) | 1.839 (1.242, 2.722) | 1.979 (1.485, 2.639) | 0.758 (0.539, 1.067) | |||||||||||||
| Tumor grade | 0.035* | 0.044* | 0.007** | 0.013* | |||||||||||||
| Low grade | 1 | 1 | 1 | 1 | |||||||||||||
| High grade | 2.609 (1.069, 6.364) | 22.925 (1.087, 483.560) | 3.405 (1.401, 8.276) | 0.566 (0.363, 0.885) | |||||||||||||
| Pathological stage T | |||||||||||||||||
| pT2 | 1 | 1 | 1 | 1 | |||||||||||||
| pT3 | 1.645 (1.150, 2.352) | 0.006** | 2.098 (1.341, 3.281) | 0.001** | 1.899 (1.376, 2.623) | <0.001** | 0.889 (0.661, 1.194) | 0.433 | |||||||||
| pT4 | 3.429 (1.881, 6.251) | <0.001** | 4.891 (2.471, 9.681) | <0.001** | 3.906 (2.297, 6.641) | <0.001** | 0.206 (0.051, 0.836) | 0.027* | |||||||||
Cl, confidence; HR, hazard ratio; OS, overall survival; CSS, cancer-specific survival; DFS, disease-free survival; BRFS, Bladder Recurrence-free survival.
* < 0.05, ** < 0.01.
UTUC, upper tract urothelial carcinoma; LND, lymph node dissection; BC, bladder cancer; ESRD, end-stage renal disease; NU, nephroureterectomy.